Root Financial Partners LLC Buys 3,703 Shares of Merck & Co., Inc. $MRK

Root Financial Partners LLC grew its stake in Merck & Co., Inc. (NYSE:MRK) by 30.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,805 shares of the company’s stock after buying an additional 3,703 shares during the quarter. Root Financial Partners LLC’s holdings in Merck & Co., Inc. were worth $2,297,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Round Rock Advisors LLC lifted its holdings in Merck & Co., Inc. by 0.7% in the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after acquiring an additional 66 shares during the period. Cypress Wealth Services LLC boosted its position in Merck & Co., Inc. by 0.5% in the 3rd quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock worth $1,960,000 after purchasing an additional 69 shares in the last quarter. Cascade Financial Partners LLC boosted its position in Merck & Co., Inc. by 0.5% in the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after purchasing an additional 80 shares in the last quarter. Somerset Trust Co grew its stake in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after purchasing an additional 81 shares during the period. Finally, Stonebridge Financial Group LLC grew its stake in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock worth $1,124,000 after purchasing an additional 81 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported Phase 3 INTerpath-001 results showing that intismeran autogene combined with KEYTRUDA reduced the risk of melanoma recurrence or death by 42%, while also improving distant metastasis-free survival. The data met market expectations and could support a future expansion of Merck’s oncology pipeline beyond KEYTRUDA. Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
• Positive Sentiment: The European Commission approved KEYTRUDA plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer. The wider label expands the addressable market for Merck’s leading oncology franchise and may help offset future pressure from slowing KEYTRUDA growth. European Commission approves KEYTRUDA plus Padcev
• Neutral Sentiment: Trading activity included approximately 37,444 MRK call options, about 40% above average daily volume, indicating increased speculative interest but not establishing a clear direction for the shares.
• Negative Sentiment: An apparent early leak of the melanoma-vaccine data caused volatility and appears to have prompted profit-taking. Investors may have expected a larger-than-reported benefit despite the statistically and clinically positive results, creating a sell-the-news response ahead of the formal ESMO presentation. Moderna, Merck shares fall after possible melanoma data leak
• Negative Sentiment: Analysts expect Merck’s upcoming third-quarter earnings to decline, limiting near-term enthusiasm and reinforcing concerns about moderating KEYTRUDA growth. Zacks also reportedly downgraded MRK from “hold” to “strong sell,” adding pressure to sentiment.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on MRK. Royal Bank Of Canada decreased their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a research note on Monday, October 12th. Zacks Research downgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a report on Monday. Wolfe Research raised their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Sanford C. Bernstein lifted their price objective on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a report on Tuesday, August 4th. Finally, Leerink Partners upped their price objective on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Seventeen research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $151.92.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $147.40 on Friday. The firm has a 50-day simple moving average of $146.79 and a 200-day simple moving average of $130.07. The stock has a market capitalization of $363.67 billion, a price-to-earnings ratio of 117.92, a price-to-earnings-growth ratio of 6.92 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were issued a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Insiders Place Their Bets

In other news, EVP David Williams sold 52,847 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the transaction, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.